Education
About Us
Working with TipRanks
Follow Us
Paradigm Biopharmaceuticals Ltd. (AU:PAR)
:PAR
PAR Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.17 - AU$0.66
Previous CloseN/A
Volume3.26M
Average Volume (3M)1.22M
Market Cap
AU$116.83M
Enterprise ValueAU$71.72M
Total Cash (Recent Filing)AU$83.93M
Total Debt (Recent Filing)AU$389.78K
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Aug 29, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding389,428,830
10 Day Avg. Volume1,101,038
30 Day Avg. Volume1,216,100
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6584.01
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.79Price Target Upside164.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Paradigm Biopharmaceuticals Ltd. News
PremiumCompany Announcements
Paradigm Biopharmaceuticals to Present at NWR Virtual Healthcare Conference
PremiumCompany Announcements
Paradigm Biopharmaceuticals Director Acquires New Options
PremiumCompany Announcements
Paradigm Biopharmaceuticals Announces Director’s Securities Interest Update
PremiumCompany Announcements
Paradigm Biopharmaceuticals Amends Bonus Issue Announcement
PremiumCompany Announcements
Paradigm Biopharmaceuticals Announces Strategic Bonus Issue of Securities---
Options Prices
Currently, No data available
---
Ownership Overview
5.69% Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
94.31% Public Companies and
Individual Investors
PAR FAQ
What was Paradigm Biopharmaceuticals Ltd.’s price range in the past 12 months?
Paradigm Biopharmaceuticals Ltd. lowest share price was AU$0.17 and its highest was AU$0.66 in the past 12 months.
What is Paradigm Biopharmaceuticals Ltd.’s market cap?
Paradigm Biopharmaceuticals Ltd.’s market cap is AU$116.83M.
When is Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date?
Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 29, 2025 which is in 144 days.
How were Paradigm Biopharmaceuticals Ltd.’s earnings last quarter?
Paradigm Biopharmaceuticals Ltd. released its earnings results on Feb 27, 2025. The company reported -AU$0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.017.
Is Paradigm Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Paradigm Biopharmaceuticals Ltd.’s price is currently Undervalued.
Does Paradigm Biopharmaceuticals Ltd. pay dividends?
Paradigm Biopharmaceuticals Ltd. does not currently pay dividends.
What is Paradigm Biopharmaceuticals Ltd.’s EPS estimate?
Paradigm Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Paradigm Biopharmaceuticals Ltd. have?
Paradigm Biopharmaceuticals Ltd. has 389,428,830 shares outstanding.
What happened to Paradigm Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Paradigm Biopharmaceuticals Ltd. reported an EPS of -AU$0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.259%.
Which hedge fund is a major shareholder of Paradigm Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:PAR
---
Paradigm Biopharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.79 (164.77% Upside)
AU$0.79 (164.77% Upside)
Blogger Sentiment
Bullish
AU:PAR Sentiment 70%
Sector Average 68%
Sector Average 68%
Insider Transactions
Bought Shares
Worth $77.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.77%
12-Months-Change
Fundamentals
Return on Equity
-46.65%
Trailing 12-Months
Asset Growth
-28.77%
Trailing 12-Months
Company Description
Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
---
PAR Stock 12 Month Forecast
Average Price Target
AU$0.79
▲(164.77% Upside)
Technical Analysis
Biotron Limited
―
Opthea Limited
―
CSL
―
Immutep Ltd
―
Medical Developments International Limited
―
Best Analysts Covering PAR
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-36.79%
reiterated a buy rating 2 months ago
Copying John Hester's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -36.79% per trade.
---